PTPRC (P08575) variants and mutations
PTPRC (also known as P08575) is a human protein-coding gene encoding a receptor-type tyrosine-protein phosphatase C protein. It controls phosphorylation of Src-family kinases and is essential for effective antigen-receptor signaling in nearly all nucleated blood cells. Biallelic loss-of-function variants can cause severe combined immunodeficiency. This analysis covers 1,829 PTPRC variants and mutations. Of these, 67% have computational variant effect predictions. Disease context includes immunodeficiency 104, immunodeficiency 105, and T-B+ severe combined immunodeficiency due to JAK3 deficiency. Example PTPRC variants include M1?, M1I, and T2I.
Variant analysis overview
- Gene: PTPRC
- Protein: P08575
- UniProt accession: P08575
- Organism: Homo sapiens
- Variants analyzed: 1829
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,637 unspecified-consequence records; 104 missense variants; 62 synonymous variants; 2 splice-region variants; 13 frameshift variants; 3 stop-gained variants; 4 stop lost; 1 stop retained variant; 1 in-frame insertions; 1 in-frame deletions; 1 substitution
- Prediction scores: 1,229 variants have prediction scores (67% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 104, immunodeficiency 105, T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to CD45 deficiency, asthma, Omenn syndrome, T-B+ severe combined immunodeficiency, T-B- severe combined immunodeficiency, respiratory system disorder, Graves disease, systemic lupus erythematosus, lung carcinoma.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 4 domains; 3 binding sites; 26 post-translational modification sites.
- Structural context: 924 variants have structural context.
- PTM context: 30 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PTPRC variants
Examples include M1?, M1I, T2I, T2N, T2S, T2T, M3I, M3T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, cosmic curated COSV10526, NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- M1I (p.Met1Ile), rs759182888, ClinGen CA36176090, ClinVar RCV001975549, ClinVar RCV003987949, MetaLR 0.01, MetaSVM -0.90, Uncertain significance, not specified; Immunodeficiency 104
- T2I (p.Thr2Ile), ExAC rs768227005, gnomAD rs768227005
- T2N (p.Thr2Asn), ExAC rs768227005, gnomAD rs768227005, CADD 21.50, PolyPhen-2 0.06
- T2S (p.Thr2Ser), gnomAD 1-198639272-A-T, CADD 22.50, PolyPhen-2 0.01
- T2T (p.Thr2Thr), rs773998713, gnomAD 1-198639274-C-T, CADD 13.80
- M3I (p.Met3Ile), rs1662439770, ClinGen CA344097961, ClinVar RCV001970474, TOPMed rs1662439770, REVEL 0.27, CADD 25.20, Uncertain significance, Immunodeficiency 104
- M3T (p.Met3Thr), ExAC rs772724488, TOPMed rs772724488, gnomAD rs772724488, REVEL 0.34, CADD 25.80
- M3V (p.Met3Val), cosmic curated COSV10466, ESP rs368929179, ExAC rs368929179, gnomAD rs368929179, REVEL 0.32, CADD 25.20
- Y4C (p.Tyr4Cys), ExAC rs773900940, gnomAD rs773900940, REVEL 0.19, CADD 22.30
- Y4S (p.Tyr4Ser), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, Variant assessed as somatic; moderate impact.
- Y4H (p.Tyr4His), gnomAD 1-198639278-T-C, REVEL 0.15, CADD 22.90
- Y4Y (p.Tyr4Tyr), rs1662440398, gnomAD 1-198639280-T-C, CADD 7.90
- L5F (p.Leu5Phe), Ensembl rs2102160135, REVEL 0.26, CADD 26.40
- L5L (p.Leu5Leu), gnomAD 1-198639283-G-A, CADD 12.70
- W6G (p.Trp6Gly), ExAC rs761069010, TOPMed rs761069010, gnomAD rs761069010, REVEL 0.31, CADD 32.00, Uncertain significance
- W6R (p.Trp6Arg), rs761069010, ClinGen CA1314363, ClinVar RCV001920629, ExAC rs761069010, REVEL 0.31, CADD 29.20, Uncertain significance, Immunodeficiency 104
- K8T (p.Lys8Thr), Ensembl rs1571765578, REVEL 0.20, CADD 25.60
- K8K (p.Lys8Lys), rs766720230, gnomAD 1-198639292-A-G, CADD 11.20
- L9L (p.Leu9Leu), gnomAD 1-198639295-C-T, CADD 2.22
- L10F (p.Leu10Phe), gnomAD rs1186725402, REVEL 0.20, CADD 25.30
- L10M (p.Leu10Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L10V (p.Leu10Val), ExAC rs61757803, TOPMed rs61757803, gnomAD rs61757803, REVEL 0.23, CADD 14.30, Uncertain significance, Inborn genetic diseases
- L10L (p.Leu10Leu), rs61757803, gnomAD 1-198639296-T-C, CADD 3.48
- L10W (p.Leu10Trp), gnomAD 1-198639297-T-G, REVEL 0.29, CADD 25.40
- A11G (p.Ala11Gly), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, NCI-TCGA Cosmic COSV6140, Variant assessed as somatic; moderate impact.
- A11S (p.Ala11Ser), ExAC rs759684142, gnomAD rs759684142, REVEL 0.18, CADD 25.90
- A11T (p.Ala11Thr), ExAC rs759684142, gnomAD rs759684142, REVEL 0.16, CADD 24.20
- A11A (p.Ala11Ala), rs1419103961, gnomAD 1-198639301-A-G, CADD 2.67
- F12I (p.Phe12Ile), Ensembl rs1662443442
- F12F (p.Phe12Phe), gnomAD 1-198639304-T-C, CADD 7.00
- G13D (p.Gly13Asp), gnomAD rs1426202766, REVEL 0.19, CADD 23.50
- G13A (p.Gly13Ala), gnomAD 1-198639306-G-C, REVEL 0.09, CADD 16.80
- G13G (p.Gly13Gly), rs141414674, gnomAD 1-198639307-C-T, CADD 12.80
- F14L (p.Phe14Leu), gnomAD 1-198639308-T-C, REVEL 0.07, CADD 22.40
- A15V (p.Ala15Val), ExAC rs752797028, gnomAD rs752797028, REVEL 0.20, CADD 12.90
- F16L (p.Phe16Leu), gnomAD rs1662444892, REVEL 0.11, CADD 18.10
- F16I (p.Phe16Ile), gnomAD 1-198639314-T-A, REVEL 0.12, CADD 22.50
- L17L (p.Leu17Leu), rs758522951, gnomAD 1-198639317-C-T, CADD 13.80
- L17P (p.Leu17Pro), gnomAD 1-198639318-T-C, REVEL 0.30, CADD 28.20
- D18H (p.Asp18His), cosmic curated COSV10072, ExAC rs781080051, TOPMed rs781080051, gnomAD rs781080051, REVEL 0.16, CADD 26.10, Uncertain significance
- D18N (p.Asp18Asn), rs781080051, ClinGen CA344098056, ClinVar RCV001046302, ExAC rs781080051, REVEL 0.09, CADD 23.90, Uncertain significance, Immunodeficiency 104
- D18A (p.Asp18Ala), gnomAD 1-198639321-A-C, REVEL 0.16, CADD 25.80
- D18D (p.Asp18Asp), rs1390547849, gnomAD 1-198639322-C-T, CADD 9.14
- T19T (p.Thr19Thr), rs199852332, gnomAD 1-198639325-A-C, CADD 5.79
- E20G (p.Glu20Gly), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, Variant assessed as somatic; moderate impact.
- E20D (p.Glu20Asp), gnomAD 1-198639328-A-T, REVEL 0.02, CADD 6.61
- E20E (p.Glu20Glu), rs1234832172, gnomAD 1-198694034-G-A, CADD 2.79
- E20A (p.Glu20Ala), rs1384885724, gnomAD 1-198694036-A-C, CADD 3.76
- V21L (p.Val21Leu), rs1288480100, NCI-TCGA Cosmic COSV6142, cosmic curated COSV61421, gnomAD rs1288480100, REVEL 0.08, CADD 9.94, Variant assessed as somatic; moderate impact.
- V23M (p.Val23Met), NCI-TCGA Cosmic COSV6141, cosmic curated COSV61418, Variant assessed as somatic; moderate impact.
- T24A (p.Thr24Ala), gnomAD 1-198639338-A-G, REVEL 0.03, CADD 2.38
- T24K (p.Thr24Lys), gnomAD 1-198639339-C-A, REVEL 0.15, CADD 14.80
- G25=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
- G25E (p.Gly25Glu), gnomAD rs1174394984, REVEL 0.19, CADD 23.30
- G25R (p.Gly25Arg), NCI-TCGA Cosmic COSV6142, cosmic curated COSV61422, Variant assessed as somatic; moderate impact.
- G25V (p.Gly25Val), NCI-TCGA TCGA novel, REVEL 0.23, CADD 23.60, Variant assessed as somatic; moderate impact.
- G25G (p.Gly25Gly), rs1314781742, gnomAD 1-198692348-G-A, CADD 3.29
- Q26K (p.Gln26Lys), ExAC rs752958303, gnomAD rs752958303, REVEL 0.03, CADD 0.29
- Q26* (p.Gln26Ter), gnomAD 1-198692349-C-T, CADD 28.80
- Q26R (p.Gln26Arg), gnomAD 1-198692350-A-G, REVEL 0.07, CADD 7.79
- Q26H (p.Gln26His), gnomAD 1-198692351-A-T, REVEL 0.02, CADD 16.00
- Q26Q (p.Gln26Gln), gnomAD 1-198692351-A-G, CADD 0.94
- S27I (p.Ser27Ile), ExAC rs763020424, gnomAD rs763020424, REVEL 0.04, CADD 0.00
- S27N (p.Ser27Asn), ExAC rs763020424, gnomAD rs763020424, REVEL 0.01, CADD 0.00
- S27A (p.Ser27Ala), gnomAD 1-198692349-CA-C, CADD 17.40
- S27G (p.Ser27Gly), gnomAD 1-198692352-A-G, REVEL 0.01, CADD 0.00
- S27T (p.Ser27Thr), gnomAD 1-198692353-G-C, REVEL 0.00, CADD 0.00
- S27R (p.Ser27Arg), gnomAD 1-198692354-C-G, REVEL 0.05, CADD 0.00
- S27S (p.Ser27Ser), gnomAD 1-198692354-C-T, CADD 0.18
- P28L (p.Pro28Leu), ExAC rs750318458, TOPMed rs750318458, gnomAD rs750318458, REVEL 0.03, CADD 0.02
- P28Q (p.Pro28Gln), gnomAD 1-198692353-GC-G, CADD 0.71
- P28S (p.Pro28Ser), gnomAD 1-198692355-C-T, REVEL 0.03, CADD 0.00
- P28T (p.Pro28Thr), gnomAD 1-198692355-C-A, REVEL 0.01, CADD 0.00
- P28R (p.Pro28Arg), gnomAD 1-198692356-C-G, REVEL 0.04, CADD 0.00
- P28P (p.Pro28Pro), gnomAD 1-198692357-A-T, CADD 0.48
- T29I (p.Thr29Ile), Ensembl rs1665976097, REVEL 0.04, CADD 0.26
- T29S (p.Thr29Ser), gnomAD 1-198692358-A-T, REVEL 0.17, CADD 0.00
- T29A (p.Thr29Ala), gnomAD 1-198692358-A-G, REVEL 0.23, CADD 0.00
- T29K (p.Thr29Lys), gnomAD 1-198692359-C-A, REVEL 0.05, CADD 0.14
- T29R (p.Thr29Arg), gnomAD 1-198692359-C-G, REVEL 0.07, CADD 0.08
- T29T (p.Thr29Thr), gnomAD 1-198692360-A-G, CADD 0.28
- P30T (p.Pro30Thr), gnomAD 1-198692361-C-A, REVEL 0.03, CADD 0.00
- P30S (p.Pro30Ser), gnomAD 1-198692361-C-T, REVEL 0.01, CADD 0.00
- P30H (p.Pro30His), gnomAD 1-198692362-C-A, REVEL 0.11, CADD 3.92
- P30P (p.Pro30Pro), gnomAD 1-198692363-T-C, CADD 4.42
- S31F (p.Ser31Phe), cosmic curated COSV61417, TOPMed rs1665976396, REVEL 0.11, CADD 20.40
- S31P (p.Ser31Pro), gnomAD 1-198692362-CT-C, CADD 16.40
- S31T (p.Ser31Thr), gnomAD 1-198692364-T-A, REVEL 0.00, CADD 0.00
- S31Y (p.Ser31Tyr), gnomAD 1-198692365-C-A, REVEL 0.12, CADD 20.20
- S31S (p.Ser31Ser), gnomAD 1-198692366-C-A, CADD 0.41
- P32L (p.Pro32Leu), Ensembl rs1665976678, REVEL 0.21, CADD 0.17
- P32T (p.Pro32Thr), gnomAD 1-198692367-C-A, REVEL 0.29, CADD 0.01
- P32S (p.Pro32Ser), gnomAD 1-198692367-C-T, REVEL 0.27, CADD 0.01
- P32H (p.Pro32His), gnomAD 1-198692368-C-A, REVEL 0.21, CADD 0.37
- P32P (p.Pro32Pro), rs756012027, gnomAD 1-198692369-C-G, CADD 0.77
- T33H (p.Thr33His), gnomAD 1-198692364-T-TC, CADD 21.30
- T33L (p.Thr33Leu), gnomAD 1-198692364-TC-T, CADD 19.90
- T33A (p.Thr33Ala), gnomAD 1-198692370-A-G, REVEL 0.03, CADD 0.00
- T33P (p.Thr33Pro), gnomAD 1-198692370-A-C, REVEL 0.24, CADD 0.01
- T33S (p.Thr33Ser), gnomAD 1-198692370-A-T, REVEL 0.03, CADD 0.00
- T33I (p.Thr33Ile), gnomAD 1-198692371-C-T, REVEL 0.06, CADD 0.05
- T33N (p.Thr33Asn), gnomAD 1-198692371-C-A, REVEL 0.01, CADD 0.00
- T33T (p.Thr33Thr), gnomAD 1-198692372-T-C, CADD 9.31
- G34* (p.Gly34Ter), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, CADD 53.00, Variant assessed as somatic; high impact.
- G34E (p.Gly34Glu), ExAC rs753850217, TOPMed rs753850217, gnomAD rs753850217, REVEL 0.08, CADD 23.50
- G34R (p.Gly34Arg), gnomAD 1-198692373-G-A, REVEL 0.05, CADD 36.00
- G34D (p.Gly34Asp), rs1191013469, gnomAD 1-198694018-G-A, CADD 1.14
- L35S (p.Leu35Ser), ESP rs369827350, ExAC rs369827350, TOPMed rs369827350, gnomAD rs369827350, REVEL 0.21, CADD 0.00
- L35L (p.Leu35Leu), gnomAD 1-198694023-C-T, CADD 3.62
- L35R (p.Leu35Arg), gnomAD 1-198694024-T-G, CADD 3.02
- T36I (p.Thr36Ile), gnomAD 1-198696718-C-T, REVEL 0.06, CADD 2.79
- T37A (p.Thr37Ala), NCI-TCGA Cosmic COSV6142, gnomAD rs1666220314, REVEL 0.03, CADD 0.03, Variant assessed as somatic; moderate impact.
- A38G (p.Ala38Gly), Ensembl rs1666220566
- A38V (p.Ala38Val), Ensembl rs1666220566, CADD 3.74
- A38A (p.Ala38Ala), rs917339656, gnomAD 1-198696725-A-G, CADD 5.50
- K39T (p.Lys39Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K39R (p.Lys39Arg), gnomAD 1-198692375-TA-T, CADD 19.80
- K39E (p.Lys39Glu), gnomAD 1-198692376-A-G, CADD 12.20
- K39Q (p.Lys39Gln), gnomAD 1-198694068-A-C, CADD 1.23
- K39N (p.Lys39Asn), rs1666072191, gnomAD 1-198694070-A-C, CADD 2.85
- M40I (p.Met40Ile), rs1571844516, ClinGen CA344096721, ClinVar RCV000818463, Ensembl rs1571844516, REVEL 0.04, CADD 0.39, Uncertain significance, Immunodeficiency 104
- M40L (p.Met40Leu), gnomAD 1-198696729-A-T, REVEL 0.05, CADD 4.97
- P41L (p.Pro41Leu), gnomAD rs1471347474, REVEL 0.12, CADD 11.50
- P41S (p.Pro41Ser), gnomAD 1-198696732-C-T, REVEL 0.06, CADD 0.01
- P41H (p.Pro41His), gnomAD 1-198696733-C-A, REVEL 0.18, CADD 19.30
- P41P (p.Pro41Pro), gnomAD 1-198696734-C-G, CADD 4.09
- S42G (p.Ser42Gly), NCI-TCGA Cosmic COSV1007, NCI-TCGA Cosmic COSV6140, Variant assessed as somatic; moderate impact.
- S42I (p.Ser42Ile), rs1159457079, ClinGen CA344096733, ClinVar RCV000801394, ClinVar RCV006367348, AlphaMissense 0.13, MetaLR 0.01, Uncertain significance, Inborn genetic diseases; Immunodeficiency 104
- S42N (p.Ser42Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S42T (p.Ser42Thr), gnomAD rs1159457079, REVEL 0.10, AlphaMissense 0.13, Uncertain significance
- S42S (p.Ser42Ser), gnomAD 1-198694046-C-T, CADD 1.87
- V43A (p.Val43Ala), ExAC rs765181971, gnomAD rs765181971, REVEL 0.02, CADD 0.07
- P44L (p.Pro44Leu), NCI-TCGA Cosmic COSV1007, REVEL 0.06, CADD 0.06, Variant assessed as somatic; moderate impact.
- P44S (p.Pro44Ser), NCI-TCGA Cosmic COSV6140, Variant assessed as somatic; moderate impact.
- P44P (p.Pro44Pro), rs115797104, gnomAD 1-198696743-A-G, CADD 3.18
- S46Y (p.Ser46Tyr), rs560218157, gnomAD 1-198694051-C-A, CADD 1.31
- S46F (p.Ser46Phe), rs560218157, gnomAD 1-198694051-C-T, CADD 1.60
- S46S (p.Ser46Ser), rs1301675062, gnomAD 1-198694052-C-A, CADD 0.29
- S47G (p.Ser47Gly), rs149488488, ClinGen CA1314415, ClinVar RCV001340251, ClinVar RCV003346491, REVEL 0.11, CADD 0.54, Conflicting interpretations, Inborn genetic diseases; Immunodeficiency 104
- S47P (p.Ser47Pro), rs1666071661, gnomAD 1-198694056-T-C, CADD 2.81
- S47L (p.Ser47Leu), rs1321359193, gnomAD 1-198694057-C-T, CADD 3.12
- S47S (p.Ser47Ser), gnomAD 1-198694058-A-C, CADD 2.24
- D48E (p.Asp48Glu), TOPMed rs1271131973
- D48V (p.Asp48Val), TOPMed rs1666222634, gnomAD rs1666222634, REVEL 0.24, CADD 0.03
- D48Y (p.Asp48Tyr), rs1344830382, gnomAD 1-198694083-G-T, CADD 3.06
- D48D (p.Asp48Asp), rs1019687765, gnomAD 1-198694085-C-T, CADD 3.40
- D48G (p.Asp48Gly), gnomAD 1-198696754-A-G, REVEL 0.16, CADD 0.01
- P49L (p.Pro49Leu), NCI-TCGA Cosmic COSV6141, Variant assessed as somatic; moderate impact.
- P49S (p.Pro49Ser), ExAC rs746480752, TOPMed rs746480752, gnomAD rs746480752, REVEL 0.13, CADD 23.50, Uncertain significance
- P49T (p.Pro49Thr), rs746480752, ClinGen CA1314417, ClinVar RCV002049517, ExAC rs746480752, REVEL 0.16, CADD 23.30, Uncertain significance, Immunodeficiency 104
- P49P (p.Pro49Pro), rs781547834, gnomAD 1-198696758-C-A, CADD 7.34
- L50S (p.Leu50Ser), NCI-TCGA Cosmic COSV1007, Variant assessed as somatic; moderate impact.
- L50F (p.Leu50Phe), gnomAD 1-198694065-C-T, CADD 1.98
- L50L (p.Leu50Leu), gnomAD 1-198694067-C-A, CADD 1.25
- P51H (p.Pro51His), NCI-TCGA Cosmic COSV9904, TOPMed rs1279852502, gnomAD rs1279852502, REVEL 0.14, CADD 23.60, Variant assessed as somatic; moderate impact.
- P51L (p.Pro51Leu), TOPMed rs1279852502, gnomAD rs1279852502, REVEL 0.16, CADD 23.40
- P51S (p.Pro51Ser), rs746435286, ExAC rs746435286, gnomAD rs746435286, REVEL 0.12, CADD 23.80, Variant assessed as somatic; moderate impact.
- P51P (p.Pro51Pro), gnomAD 1-198696764-T-C, CADD 8.92
- T52A (p.Thr52Ala), rs114764326, ClinGen CA1314421, ClinVar RCV000640075, ClinVar RCV003420122, REVEL 0.03, CADD 9.05, Benign/Likely benign, Inborn genetic diseases; not provided; Immunodeficiency 104
- T52I (p.Thr52Ile), rs1558004385, gnomAD 1-198696765-AC-A, CADD 24.60
- T52S (p.Thr52Ser), gnomAD 1-198696765-A-T, REVEL 0.05, CADD 14.50
- H53D (p.His53Asp), TOPMed rs951948469
- H53Q (p.His53Gln), TOPMed rs1666224310, gnomAD rs1666224310, REVEL 0.15, CADD 19.50
- H53R (p.His53Arg), rs1462459543, gnomAD 1-198694021-A-G, CADD 0.72
- H53H (p.His53His), gnomAD 1-198694022-T-C, CADD 3.03
- H53Y (p.His53Tyr), gnomAD 1-198694134-C-T, CADD 1.91
- H53P (p.His53Pro), rs1195596817, gnomAD 1-198694135-A-C, CADD 4.34
- T54A (p.Thr54Ala), ExAC rs775839710, gnomAD rs775839710, REVEL 0.08, CADD 22.90
- T54N (p.Thr54Asn), gnomAD rs1203601910, REVEL 0.11, CADD 18.90
- T54S (p.Thr54Ser), gnomAD rs1203601910, REVEL 0.07, CADD 13.40
- T54T (p.Thr54Thr), rs1294125895, gnomAD 1-198696773-C-A, CADD 9.57
- T55T (p.Thr55Thr), rs1428187819, gnomAD 1-198696776-T-C, CADD 7.48
- A56S (p.Ala56Ser), TOPMed rs1490524921, gnomAD rs1490524921, REVEL 0.14, CADD 15.50
- A56D (p.Ala56Asp), rs1361312906, gnomAD 1-198694081-C-A, CADD 1.51
- A56P (p.Ala56Pro), gnomAD 1-198696777-G-C, REVEL 0.13, CADD 23.30
- A56A (p.Ala56Ala), gnomAD 1-198696779-A-G, CADD 10.80
- S58L (p.Ser58Leu), TOPMed rs1666225106, CADD 2.06
- S58R (p.Ser58Arg), gnomAD 1-198694086-A-C, CADD 2.76
- S58A (p.Ser58Ala), gnomAD 1-198696783-T-G, REVEL 0.09, CADD 17.60
Public PTPRC analysis runs
- PTPRC analysis run — PTPRC (1,829 variants) — completed 2026-08-19